Visfatin is not associated with inflammatory markers in patients on hemodialysis

Clin Lab. 2013;59(11-12):1253-9.

Abstract

Background: Cardiovascular events are a major cause of death in patients with end-stage renal disease. Endothelial dysfunction represents a key event in atherosclerosis development and has been implicated in the pathophysiology of different forms of cardiovascular disease, including chronic kidney disease. In recent years, visfatin, a ubiquitous adipokine, has been described as a potent marker of endothelial inflammation and dysfunction. The aim of the study was to investigate the association of visfatin with well-known markers of inflammation and endothelial dysfunction.

Methods: Serum and plasma samples from 66 patients (40 males and 26 females) treated by hemodialysis were analysed for visfatin, fibrinogen, CRP, PAI-1 levels. Visfatin was determined by ELISA method while CRP, fibrinogen and PAL-1 were obtained by standard laboratory methods.

Results: We observed statistically significant correlation between visfatin level and fibrinogen (r = 0.51; p = 0.008) and the time on dialysis in female patients (r = 0.70; p < 0.001). PAI-1 and CRP did not correlate with visfatin in males nor in females.

Conclusions: Visfatin is correlated with time on dialysis and with fibrinogen only in female dialysis patients. To confirm this, further studies are needed with a higher number of patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / blood*
  • C-Reactive Protein / analysis
  • Cross-Sectional Studies
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fibrinogen / analysis
  • Humans
  • Inflammation / blood*
  • Male
  • Middle Aged
  • Nicotinamide Phosphoribosyltransferase / blood*
  • Plasminogen Activator Inhibitor 1 / blood
  • Renal Dialysis*

Substances

  • Biomarkers
  • Plasminogen Activator Inhibitor 1
  • Fibrinogen
  • C-Reactive Protein
  • Nicotinamide Phosphoribosyltransferase